Keyphrases
Gut Microbiome
100%
Fatty Acid Oxidation
100%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Glutathione Synthesis
100%
Glycine
100%
Nonalcoholic Steatohepatitis
57%
Steatohepatitis
28%
Lipids
28%
Transcriptomics
28%
Hepatic Fatty Acid Oxidation
28%
Clinical Evaluation
14%
Inflammation
14%
Therapeutic Potential
14%
Glucose-lowering Drugs
14%
Causal Factors
14%
Liver
14%
Hepatic Fibrosis
14%
NF-B
14%
Body Composition
14%
Oxidation Mechanism
14%
Pharmacological Therapy
14%
Tripeptide
14%
Metagenomics
14%
Diet-induced
14%
Inflammatory Cytokines
14%
Potential Therapy
14%
Metabolomics
14%
Inflammatory Infiltration
14%
Transaminases
14%
Smad Signaling
14%
High Cholesterol
14%
Bacterial Genera
14%
Biosynthetic Genes
14%
Glycine Metabolism
14%
Dietary Approaches
14%
Gly-Gly-His
14%
Lipotoxicity
14%
Alanine-glyoxylate Aminotransferase
14%
High-fat High-fructose Diet
14%
Clostridium Sensu Stricto
14%
Peroxisomal Fatty Acid Oxidation
14%
Medicine and Dentistry
Gut Microbiome
100%
Nonalcoholic Fatty Liver
100%
Fatty Acid Oxidation
100%
Glutathione Metabolism
100%
Transcriptomics
18%
Steatohepatitis
18%
Cytokine
9%
Clinical Trial
9%
Hyperlipidemia
9%
Liver Fibrosis
9%
Drug Therapy
9%
High Fat Food
9%
Clostridium
9%
High-Fructose Diet
9%
Transaminase
9%
Metabolomics
9%
Cholesterol Diet
9%
Tripeptide
9%
Lipotoxicity
9%
Alanine Glyoxylate Aminotransferase
9%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Fatty Acid
100%
Glutathione
100%
Microbiome
100%
Clinical Trial
9%
Pharmacotherapy
9%
Inflammation
9%
Fructose
9%
Hyperlipidemia
9%
Liver Fibrosis
9%
Aminotransferase
9%
Cytokine
9%
Tripeptide
9%
Clostridium
9%
Lipotoxicity
9%
Alanine Glyoxylate Aminotransferase
9%